Fig. 4From: Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort studyModerate or severe exacerbation in the prompt and delayed therapy populations with index date after November 1, 2013 (LAMA + LABA product launch). CI confidence interval, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonistBack to article page